Puma Biotechnology
Mirati Therapeutics Inc - Sponsored Research: Mirati Therapeutics, Inc; Boehringer-Ingelheim; Eli Lilly and Company; Takeda Oncology; Puma Biotechnology; Astellas Pharmaceuticals; AstraZeneca; Daiichi Sankyo; Revolution Medicines Consulting Fees ...
Puma Biotechnology's Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (
APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio - TheStreet
Puma Biotechnology
RETRACTED ARTICLE: Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway | Cancer Gene Therapy
Puma Biotechnology's Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NE
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotech to pay PPD founder $22M in defamation suit from proxy fight | Fierce Pharma
Puma Biotechnology
Puma pounces on failed Takeda drug, snapping up cancer prospect
Puma Biotechnology
Dennis Sanders - Senior Clinical Specialist - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
PUMA Induction by FoxO3a Mediates the Anticancer Activities of the Broad-Range Kinase Inhibitor UCN-01
Puma Biotechnology
Puma Biotechnology, Knight Therapeutics sign license deal to commercialize NERLYNX in Canada - Pharmaceutical Business review
Alison Dent - Senior Clinical Specialist - Breast Cancer - Puma Biotechnology, Inc. | LinkedIn
Find a Job | Puma Biotechnology, Inc.
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Knight Therapeutics licences cancer drug from Puma Biotechnology
Puma Biotechnology
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
